Supernus Pharmaceuticals (SUPN)

Executive Summary

Supernus Pharmaceuticals is a publicly traded biopharmaceutical company focused on central nervous system (CNS) disorders, with a portfolio of eight marketed products and a pipeline targeting epilepsy, depression, and movement disorders. The company's commercial portfolio, including Trokendi XR and Oxtellar XR for epilepsy and ADHD treatments, generates stable revenue, while the pipeline features late-stage candidates such as SPN-817 (focal onset seizures, Phase 2) and NV-5138 (major depressive disorder, Phase 2 completed). Supernus also leverages its proprietary drug delivery technologies and holds strategic partnerships to expand its CNS franchise. Despite generic competition risk for established products, the company maintains a solid balance sheet and is positioned for growth through pipeline advancement and potential approvals. Near-term catalysts include data readouts from ongoing trials and regulatory decisions on key assets, which could drive significant value for shareholders.

Upcoming Catalysts (preview)

• Q2 2026SPN-830 (apomorphine infusion) FDA decision for Parkinson's disease85% success
• Q3 2026NV-5138 Phase 2 data presentation in major depressive disorder60% success
• H2 2026SPN-817 Phase 2 interim data for focal onset seizures50% success